全国观察研究:[18F]FDG PET/CT甲状腺偶发瘤恶性风险低于预期
该荷兰全国性回顾观察研究分析了2012至2019年64,706例接受甲状腺细针穿刺的患者,其中3,938例(6.1%)为[18F]FDG PET甲状腺偶发瘤。PET偶发瘤组恶性率为19.4%,显著高于对照组的8.8%,但低于现行指南引用的31–33%。细胞学可疑结节中相当比例未行手术,提示诊断流程可能低效,支持更选择性的FNA策略。
要点
- [18F]FDG PET甲状腺偶发瘤恶性率为19.4%,低于指南引用的31–33%。
- PET偶发瘤组Bethesda III–VI各细胞学类别比例均显著高于对照组。
- Bethesda IV和V中分别有36%和29%未手术,提示诊断流程可能低效。
核心结论
- [18F]FDG PET甲状腺偶发瘤恶性率为19.4%,低于现行指南引用的31–33%。
- 细胞学可疑结节中相当比例未行手术,提示当前诊断方法可能存在低效。
- 研究结果支持更选择性的FNA策略和加强风险分层。
研究设计与样本
- 荷兰全国性回顾观察研究,分析Palga病理数据库2012年1月至2019年12月接受甲状腺细针穿刺的患者,随访至2022年12月。
- 共纳入64,706例患者,其中3,938例(6.1%)因[18F]FDG PET甲状腺偶发瘤行细针穿刺。
- 主要结局为[18F]FDG PET偶发瘤组与对照组的恶性风险比较,次要结局包括Bethesda分类分布和组织学亚型。
主要发现
- [18F]FDG PET甲状腺偶发瘤检出量从2012年(n=281)至2019年(n=641)增加128%。
- PET偶发瘤组患者年龄更大(中位64岁 vs. 52岁,p<0.001),男性比例更高(30.8% vs. 19.1%,p<0.001)。
- PET偶发瘤组总体恶性率显著高于对照组(19.4% vs. 8.8%,p<0.001)。
- PET偶发瘤组各可疑细胞学类别比例更高:Bethesda III(13.1% vs. 6.5%)、IV(10.2% vs. 4.3%)、V(7.3% vs. 2.9%)、VI(6.8% vs. 2.1%),均p<0.001。
- 不确定细胞学中,Bethesda IV的36%和Bethesda V的29%未行手术;乳头状甲状腺癌为主要恶性亚型(52.3%),未见未分化癌。
关键数值与推荐
- [18F]FDG PET甲状腺偶发瘤恶性率为19.4%,对照组为8.8%(p<0.001)。
- 现行指南引用[18F]FDG阳性甲状腺结节恶性率为31–33%。
- Bethesda III、IV、V、VI在PET偶发瘤组分别为13.1%、10.2%、7.3%、6.8%,对照组分别为6.5%、4.3%、2.9%、2.1%。
临床怎么用
- 对[18F]FDG PET甲状腺偶发瘤行FNA时,应结合本研究较低恶性率(19.4%)进行风险沟通。
- 考虑更选择性的FNA策略,避免对低风险偶发瘤的过度穿刺。
- 对细胞学不确定结节加强风险分层,减少不必要的手术干预。
局限性
- 回顾性观察设计,基于病理数据库文档判定PET阳性,可能存在选择偏倚和信息偏倚。
- 未报告偶发瘤的影像特征(如SUVmax)与恶性风险的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The widespread use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) has led to increased detection of thyroid incidentalomas (TIs). Current guidelines cite malignancy rates of 31–33% for [18F]FDG-positive thyroid nodules, but population-based data remain limited. This study aimed to assess the malignancy risk and cytological distribution of [18F]FDG PET TIs in a nationwide cohort. METHODS: This retrospective observational study analyzed data from the Dutch nationwide pathology databank (Palga) for all patients who underwent thyroid fine-needle aspiration between January 2012 and December 2019, with follow-up until December 2022. Patients were classified as [18F]FDG PET TI based on documentation of [18F]FDG PET positivity in pathology reports. The primary outcome was malignancy risk compared between [18F]FDG PET TI and control groups. Secondary outcomes included distribution across Bethesda System categories and histological subtypes. RESULTS: Among 64,706 patients analyzed, 3,938 (6.1%) underwent fine-needle aspiration for [18F]FDG PET thyroid incidentalomas. [18F]FDG PET TI detection increased 128% between 2012 (n = 281) and 2019 (n = 641). Patients with [18F]FDG PET TIs were older (median 64 vs. 52 years, p < 0.001) and more likely male (30.8% vs. 19.1%, p < 0.001). The overall malignancy rate was significantly higher in [18F]FDG PET TIs compared with controls (19.4% vs. 8.8%, p < 0.001). [18F]FDG PET TIs demonstrated higher proportions of suspicious cytological categories: atypia of undetermined significance (Bethesda III) (13.1% vs. 6.5%), follicular neoplasm (Bethesda IV) (10.2% vs. 4.3%), suspicious for malignancy (Bethesda V) (7.3% vs. 2.9%), and malignant cytology (Bethesda VI) (6.8% vs. 2.1%) (all p < 0.001). Among patients with indeterminate cytology, 36% of Bethesda IV and 29% of Bethesda V cases did not undergo surgery. Papillary thyroid carcinoma was the predominant malignant subtype (52.3%), with no anaplastic carcinomas observed. CONCLUSIONS: This largest population-based study demonstrates that [18F]FDG PET TIs have a malignancy rate of 19.4%, which is lower than the 31–33% cited in current guidelines. The substantial proportion of cytologically suspicious nodules that do not proceed to surgery suggests potential inefficiency in current diagnostic approaches. These findings support more selective FNA strategies and enhanced risk stratification to optimize patient care while minimizing unnecessary interventions.
引用
- Coerts HI, van Kemenade FJ, van Ginhoven TM, et al. The malignancy risk of thyroid incidentalomas detected by [18F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands. Eur J Nucl Med Mol Imaging. 2026. PMID: 41501540. doi:10.1007/s00259-025-07714-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。